GlassScriptPhysician profile
Richard J Ou
NPI 1053319301
$4,025.13
in general payments reported to CMS, 2019-2025
23 companies · $903 in 2025
The $903 reported for 2025 was more than what 75% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $844 · 2020: $212 · 2021: $500 · 2022: $417 · 2023: $388 · 2024: $761 · 2025: $903.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,052.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,052.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,088.69 | 2019-2025 | Lensx, Rocklatan, Clareon |
| Abbvie INC. | $688.81 | 2022-2025 | |
| Johnson & Johnson Surgical Vision, INC. | $347.77 | 2019-2025 | Tecnis Iol, Catalys System |
| Sun Pharmaceutical Industries INC. | $313.35 | 2019-2025 | |
| Carl Zeiss Meditec USA, INC. | $246.42 | 2021-2025 | Cirrus Hd-Oct |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $180.09 | 2019-2021 | |
| Glaukos Corporation | $155.21 | 2022-2025 | Idose, Idosetr |
| Oyster Point Pharma, INC. | $143.48 | 2022-2024 | Tyrvaya, Ryzumvi |
| Bausch & Lomb Americas INC. | $123.29 | 2023-2025 | Vyzulta, Miebo, Lotemax Sm |
| Allergan, INC. | $101.28 | 2020-2022 | |
| Thea Pharma INC. | $84.00 | 2023-2025 | Iyuzeh |
| Novartis Pharmaceuticals Corporation | $80.80 | 2019 | |
| Aerie Pharmaceuticals, INC. | $68.93 | 2020-2021 | |
| Sight Sciences, INC. | $65.23 | 2024-2025 | Omni Surgical System |
| Kala Pharmaceuticals, INC. | $62.67 | 2021-2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $57.61 | 2024-2025 | Vevye |
| Ocular Therapeutix, INC. | $39.76 | 2024 | Dextenza |
| Tarsus Pharmaceuticals, INC. | $35.99 | 2024 | Xdemvy |
| Eyevance Pharmaceuticals LLC | $35.90 | 2019 | |
| Rxsight INC | $33.19 | 2024-2025 | Rxsight Contact Lens, Light Adjustable Lens (Lal), Rxsight Injector Cartridge |
| Shire North American Group INC | $24.85 | 2019 | |
| New World Medical,INC. | $24.40 | 2024-2025 | Clearpath, Streamline, Kahook Dual Blade |
| Horizon Therapeutics Plc | $23.41 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Ou listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.